Rania M Abdou, Maged A. El Wakeel, Ghada M. El-Kassas, Walaa H. Ali, Hend M. Ahmed, Mohamed Agha, Mohamed Abdel Atti Abdel Fatah, Ramy Saleh Abdelghany, Kareem Salah Eldin Fekry Madbouly, Haidy Badei Mohamad, Iman Shawky Hassan, Mohamed Abdelsalam Mohamed Ahmed, Heba T. Okda, Hatem Attia Mostafa Ismail
Ain Shams University. Child Health Department, National Research. National Research Centre. Armed Forces College of Medicine. Jahra Hospital and Ministry of Health. Al-Azhar University. Menoufia University.
Egypt and Kuwait
La Clinica Terapeutica
Clin Ter 2026; 177: 539-548
DOI: 10.7417/CT.2026.2039
Abstract
Background: Persistent pulmonary hypertension of the newborn (PPHN) is a life-threatening condition characterized by elevated pulmonary vascular resistance and impaired oxygenation. Endothelial dysfunction plays a central role in its pathophysiology. Asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase, has been implicated in pulmonary vascular disease; however, its clinical utility as a biomarker of disease severity and therapeutic response in neonatal PPHN remains insufficiently defined.
Methods: This prospective observational case-control study included neonates diagnosed with PPHN and age- and sex-matched healthy controls. Plasma ADMA levels were measured using enzyme-linked immunosorbent assay (ELISA). Clinical severity was assessed using oxygenation index (OI) and echocardiographic parameters. Associations between ADMA levels, disease severity, and therapeutic response were analyzed using correlation analysis, multivariable regression models, and receiver operating characteristic (ROC) curve analysis.
Results: Neonates with PPHN demonstrated significantly elevated plasma ADMA levels compared with controls (p < 0.001). ADMA levels showed a positive correlation with oxygenation index and echocardiographic markers of pulmonary hypertension severity. Higher baseline ADMA concentrations were independently associated with increased disease severity after adjustment for relevant confounders. ROC curve analysis demonstrated good discriminatory performance of ADMA in identifying severe PPHN. Additionally, declining ADMA levels were associated with clinical improvement following standard therapeutic interventions.
Conclusion: Plasma ADMA levels are significantly elevated in neonates with PPHN and correlate with disease severity and therapeutic response. ADMA may serve as a promising biomarker for risk stratification and monitoring in neonatal PPHN. Larger multicenter studies are warranted to validate these findings and explore its prognostic utility.
Category
Class I. Persistent Pulmonary Hypertension of the Newborn
Diagnostic Testing for Pulmonary Vascular Disease. Non-invasive Testing
Diagnostic Testing for Pulmonary Vascular Disease. Risk Stratification
Age Focus: Pediatric Pulmonary Vascular Disease
Fresh or Filed Publication: Fresh (PHresh). Less than 1-2 years since publication
Article Access
Free PDF File or Full Text Article Available Through PubMed or DOI: Yes